30 Results
Sort By:
Published on June 29, 2018
Developing new precision therapies for heart failure using both genomic and non-genomic approaches is the goal of an expanded research effort announced today by Bayer and The Broad Institute of MIT and Harvard. Through the new Precision Cardiology Laboratory, Bayer and the Broad said, researchers aim to learn more about…
Published on January 8, 2018
SAN FRANCISCO—Regeneron Pharmaceticals said the $50 million-plus consortium it has launched with five biopharmas will reshape drug development and even human health beyond simply speeding up exome sequencing of all 500,000 people within the UK Biobank by three years. AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen and Pfizer have agreed to invest…
Published on July 23, 2024
Cardurion Pharmaceuticals has raised a $260M Series B financing led by Ascenta Capital to support development of a first-in-class phosphodiesterase-9 (PDE9) inhibitor for heart failure and a Calcium/Calmodulin-dependent Protein Kinase II (CaMKII) inhibitor with “broad therapeutic potential,” according to the company. Both drug candidates are in Phase II trials. The…
Published on April 22, 2024
Research led by the University of Pittsburgh suggests that more attention should be paid to people with atrial fibrillation who are younger than 65 years, as they have considerable health issues and a significantly increased risk of dying compared with the general population. “Common knowledge among cardiologists is that, in…
Published on April 16, 2024
Researchers at the McMaster University, in a new meta-analysis, have found that donepezil, a medication commonly prescribed for dementia does not increase the risk of death and certain heart rhythm problems, contrary to past warnings. The research, published in the Journal of the American Geriatrics Society, noted that past warnings…
Published on December 1, 2023
The American College of Cardiology (ACC) and the American Heart Association (AHA), in collaboration with other medical associations, have released a new comprehensive guideline for the prevention and management of atrial fibrillation (AFib). Published simultaneously in the Journal of the American College of Cardiology and Circulation, the guideline addresses how…
Published on November 29, 2023
Cardiologists and radiation oncologists at Washington University School of Medicine have repurposed radiation therapy, a conventional approach used against cancer, to target patients with ventricular tachycardia. Heart failure, a condition affecting approximately 6.7 million American adults, is characterized by the heart’s gradual loss of its ability to supply the body…
Published on April 19, 2023
A study led by Yale University School of Medicine shows a significant link between prenatal depression and subsequent cardiovascular disease. The study was reported in the Journal of the American Heart Association and showed women who were depressed during pregnancy had a 32–83% increased risk of developing some form of…
Published on March 15, 2023
A clinical study led by scientists at Karolinska Institute and Karolinska University Hospital in Sweden reveals how the hunger hormone ghrelin can increase cardiac pump function in patients with heart failure. According to the Heart Failure Society of America, nearly seven million Americans over the age of 20 suffer from…
Published on February 28, 2023
Results from a Phase III trial of Australian biotech Mesoblast’s mesenchymal precursor cell therapy for heart failure show improved ejection fraction and lower risk of heart attack or stroke in recipients. However, despite these signs of benefit, the study did not meet its primary endpoint, which was time to recurrent…
Published on June 17, 2022
New European recommendations stress the value of cardiac genetic testing in athletes but also outline its limitations and the importance of counseling before and afterwards. High-level exercise can lead to structural and electrical changes in the heart that can mimic inherited cardiac conditions, explain the researchers. This ‘grey zone’ can…
Published on March 23, 2022
A number of genomic testing companies and laboratories have joined forces to launch the CardioGenomic Testing Alliance (CGTA), a collaborative group with a purpose of raising awareness and the use of genomic assays to test for a variety of cardiovascular conditions. The member companies will work together to advance the…
Published on May 26, 2020
Researchers at Queen Mary University of London, the Broad Institute of MIT, and Harvard have found hundreds of new links between people’s DNA and the heart’s electrical activity, according to a study of almost 300,000 people. The research “Multi-ancestry GWAS of the electrocardiographic PR interval identifies 202 loci underlying cardiac…
Published on January 27, 2020
Researchers at Harvard may have discovered the molecular basis that can lead to cardiomyopathy in patients, as well as a new drug to treat this genetic conditions. Cardiac cells, also known as cardiomyocytes, are unique muscular cells in the body, in that they will repeatedly contract, without rest, over the…
Published on January 16, 2019
Researchers from the Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified an epigenetic marker and two genes that caused heart failure in the children and grandchildren of fruit flies with high-fat-diet-induced heart dysfunction. Reversing the epigenetic modification or over-expressing the two genes protected subsequent generations from the negative heart…